Modern Antiplatelet Therapy: When Is Clopidogrel the Right Choice?
Explore this paper's citation graph
- Type
- article
- Published
- 2018-07-01
- Cited by
- 0
- References
- 254
- Access
- Open access
- OpenAlex
- https://openalex.org/W2887980790
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:81529456
Keywords
Prasugrel, Clopidogrel, Medicine, Ticagrelor, Antiplatelet drug
References
- Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.
- Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).
- Calcium-channel blockers do not alter the clinical efficacy of clopidogrel after myocardial infarction: a nationwide cohort study.
- Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In
- Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
- Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT
- Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study.
- Pharmacokinetics and Tolerability of Single and Multiple Doses of Ticagrelor in Healthy Chinese Subjects
- Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
- The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis
- Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial.
- High versus standard clopidogrel maintenance dose after percutaneous coronary intervention and effects on platelet inhibition, endothelial function, and inflammation results of the ARMYDA-150 mg (antiplatelet therapy for reduction of myocardial damage during angioplasty) randomized study.
- Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial Inf
- Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping.
- Prasugrel (Effient), an Adenosine Diphosphate Receptor Antagonist for the Treatment Of Acute Coronary Syndrome
- Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance.
- A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placem
- Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial.
- Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice.
- Effects of Clopidogrel Added to Aspirin in Patients with Recent Lacunar Stroke
Cited by
No citing papers recorded for this paper.
Related papers
- Potent P2Y12 receptor inhibitors in patients with acute coronary syndrome
- Prasugrel hydrochloride for the treatment of acute coronary syndrome patients
- Oral antiplatelet therapy after acute coronary syndrome and percutaneous coronary intervention: balancing efficacy and bleeding risk.
- Study on antiplatelet effect of a new thiophenopyridine platelets P2Y12 receptor antagonist DV-127.
- Clinical effects and outcomes with new P2Y12 inhibitors in ACS
- Oral antiplatelet agents in ACS: from pharmacology to clinical differences
- Pharmacotherapy in the cardiac catheterization laboratory: evolution and recent developments
- Bridging antiplatelet therapy in patients requiring cardiac and non-cardiac surgery: from bench to bedside